Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | PAK4 | O96013 | 8/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 4/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010663 | 1.00 | IGF1R (0.49) | IGF1RPAK4IRAK4PLK4AURKA | |
| SCHEMBL18984843 | 1.00 | IGF1R (0.49) | IGF1RPAK4IRAK4PLK4AURKA | |
| SCHEMBL18984818 | 0.83 | PAK4 (0.43) | IGF1RPAK4IRAK4CDK1EGFR | |
| SCHEMBL19010661 | 0.83 | PAK4 (0.43) | IGF1RPAK4IRAK4CDK1EGFR | |
| SCHEMBL18984817 | 0.83 | PAK4 (0.43) | IGF1RPAK4IRAK4CDK1EGFR | |
| SCHEMBL19010669 | 0.82 | PDPK1 (0.46) | IGF1RPAK4IRAK4AURKACDK1 | |
| SCHEMBL19010664 | 0.82 | PDPK1 (0.46) | IGF1RPAK4IRAK4AURKACDK1 | |
| SCHEMBL19010660 | 0.82 | PDPK1 (0.46) | IGF1RPAK4IRAK4AURKACDK1 | |
| SCHEMBL19010666 | 0.81 | PAK4 (0.42) | IGF1RPAK4IRAK4CDK1EGFR | |
| SCHEMBL18984927 | 0.81 | PAK4 (0.42) | IGF1RPAK4IRAK4CDK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180339992-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RES INST (US) | 2018-11-29 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2017106771-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | IGF1R 1252/4885PAK4 126/4885IRAK4 164/4885 |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | IGF1R 4532/4885PAK4 324/4885IRAK4 3628/4885 |
| US-20180339992-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | LRRK2, PRKDC, DAPK2 | IGF1R 1252/4885PAK4 126/4885IRAK4 164/4885 |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | LRRK2, PRKDC, DAPK2 | IGF1R 1252/4885PAK4 126/4885IRAK4 164/4885 |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | IGF1R 1252/4885PAK4 126/4885IRAK4 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.